Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Hormone Molecular Biology and Clinical Investigation

Editor-in-Chief: Chetrite, Gérard S.

Editorial Board: Alexis, Michael N. / Baniahmad, Aria / Beato, Miguel / Bouillon, Roger / Brodie, Angela / Carruba, Giuseppe / Chen, Shiuan / Cidlowski, John A. / Clarke, Robert / Coelingh Bennink, Herjan J.T. / Darbre, Philippa D. / Drouin, Jacques / Dufau, Maria L. / Edwards, Dean P. / Falany, Charles N. / Fernandez-Perez, Leandro / Ferroud, Clotilde / Feve, Bruno / Flores-Morales, Amilcar / Foster, Michelle T. / Garcia-Segura, Luis M. / Gastaldelli, Amalia / Gee, Julia M.W. / Genazzani, Andrea R. / Greene, Geoffrey L. / Groner, Bernd / Hampl, Richard / Hilakivi-Clarke, Leena / Hubalek, Michael / Iwase, Hirotaka / Jordan, V. Craig / Klocker, Helmut / Kloet, Ronald / Labrie, Fernand / Mendelson, Carole R. / Mück, Alfred O. / Nicola, Alejandro F. / O'Malley, Bert W. / Raynaud, Jean-Pierre / Ruan, Xiangyan / Russo, Jose / Saad, Farid / Sanchez, Edwin R. / Schally, Andrew V. / Schillaci, Roxana / Schindler, Adolf E. / Söderqvist, Gunnar / Speirs, Valerie / Stanczyk, Frank Z. / Starka, Luboslav / Sutter, Thomas R. / Tresguerres, Jesús A. / Wahli, Walter / Wildt, Ludwig / Yang, Kaiping / Yu, Qi


CiteScore 2018: 2.43

SCImago Journal Rank (SJR) 2018: 0.947
Source Normalized Impact per Paper (SNIP) 2018: 0.837

Online
ISSN
1868-1891
See all formats and pricing
More options …
Volume 36, Issue 2

Issues

Liraglutide for psychiatric disorders: clinical evidence and challenges

Mehmet Akif Camkurt
  • Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Luca Lavagnino
  • Harris County Psychiatric Center, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Xiang Y. Zhang
  • Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Antonio L Teixeira
  • Corresponding author
  • Neuropsychiatry Program and Immuno-Psychiatry Lab, Department of Psychiatry and Behavioral Sciences, UT Health Houston, 1941 East Road, Houston, TX 77054, USA
  • Laboratório Interdisciplinar de Investigação Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2018-07-18 | DOI: https://doi.org/10.1515/hmbci-2018-0031

Abstract

Obesity and diabetes are both risk factors and consequences of psychiatric disorders. Glucagon like peptide 1 (GLP-1) receptor agonists such as liraglutide are widely used in the treatment of diabetes and obesity. There are considerable amounts of preclinical studies showing the effects of liraglutide on promotion of neurogenesis, while preventing apoptosis and oxidation. Preliminary clinical evidence has suggested that liraglutide could decrease weight gain, improve cognition and prevent cognitive decline. Accordingly, liraglutide has been regarded as a potential candidate for the management of psychiatric disorders. Herein, we will discuss the association between obesity/diabetes and psychiatric disorders, and the emerging use of liraglutide in psychiatry.

Keywords: Alzheimer’s disease; eating disorders; GLP-1 receptor; liraglutide; mood disorders; schizophrenia

References

  • [1]

    Simon GE, Von Korff M, Saunders K, Miglioretti DL, Crane PK, Van Belle G, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry. 2006;63:824–30.CrossrefPubMedGoogle Scholar

  • [2]

    Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry. 2004;65:13–26.PubMedGoogle Scholar

  • [3]

    Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci. 1987;84:3434–8.CrossrefGoogle Scholar

  • [4]

    Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84–90.Web of SciencePubMedCrossrefGoogle Scholar

  • [5]

    Meloni AR, DeYoung MB, Lowe C, Parkes DG. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes Obes Metab. 2013;15:15–27.Web of SciencePubMedCrossrefGoogle Scholar

  • [6]

    Hunter K, Hölscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13:33.CrossrefPubMedWeb of ScienceGoogle Scholar

  • [7]

    Hamilton A, Patterson S, Porter D, Gault VA, Holscher C. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res. 2011;89:481–9.PubMedCrossrefWeb of ScienceGoogle Scholar

  • [8]

    Li Y, Bader M, Tamargo I, Rubovitch V, Tweedie D, Pick CG, et al. Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. J Neurochem. 2015;135:1203–17.CrossrefWeb of SciencePubMedGoogle Scholar

  • [9]

    McClean PL, Gault VA, Harriott P, Hölscher C. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer’s disease. Eur J Pharmacol. 2010;630:158–62.CrossrefWeb of ScienceGoogle Scholar

  • [10]

    Farr OM, Sofopoulos M, Tsoukas MA, Dincer F, Thakkar B, Sahin-Efe A, et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue Liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia. 2016;59:954–65.Web of SciencePubMedGoogle Scholar

  • [11]

    Parthsarathy V, Hölscher C. The type 2 diabetes drug Liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. Eur J Pharmacol. 2013;700:42–50.PubMedCrossrefWeb of ScienceGoogle Scholar

  • [12]

    Briyal S, Shah S, Gulati A. Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia. Neuroscience. 2014;281:269–81.Web of ScienceCrossrefPubMedGoogle Scholar

  • [13]

    Zhao Z, Okusaga OO, Quevedo J, Soares JC, Teixeira AL. The potential association between obesity and bipolar disorder: a meta-analysis. J Affect Disord. 2016;202:120–3.CrossrefPubMedWeb of ScienceGoogle Scholar

  • [14]

    McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, Nemeroff CB. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry. 2004;65:634–51.CrossrefPubMedGoogle Scholar

  • [15]

    Aronne LJ, Segal KR. Weight gain in the treatment of mood disorders. J Clin Psychiatry. 2003;64:22–9.PubMedGoogle Scholar

  • [16]

    Hendrick V, Altshuler L, Whybrow P. Psychoneuroendocrinology of mood disorders: the hypothalamic-pituitary-thyroid axis. Psychiatr Clin. 1998;21:277–92.Google Scholar

  • [17]

    Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24:1069–78.PubMedCrossrefGoogle Scholar

  • [18]

    Carnethon MR, Kinder LS, Fair JM, Stafford RS, Fortmann SP. Symptoms of depression as a risk factor for incident diabetes: findings from the National Health and Nutrition Examination Epidemiologic Follow-up Study, 1971–1992. Am J Epidemiol. 2003;158:416–23.CrossrefPubMedGoogle Scholar

  • [19]

    Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx B, Elzinga BM. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry. 2014;19:791.CrossrefWeb of SciencePubMedGoogle Scholar

  • [20]

    Rao AA, Sridhar GR, Srinivas B, Das UN. Bioinformatics analysis of functional protein sequences reveals a role for brain-derived neurotrophic factor in obesity and type 2 diabetes mellitus. Med Hypotheses. 2008;70:424–9.PubMedWeb of ScienceCrossrefGoogle Scholar

  • [21]

    Koshal P, Kumar P. Effect of Liraglutide on corneal kindling epilepsy induced depression and cognitive impairment in mice. Neurochem Res. 2016;41:1741–50.Web of ScienceCrossrefPubMedGoogle Scholar

  • [22]

    Kamble M, Gupta R, Rehan HS, Gupta LK. Neurobehavioral effects of liraglutide and sitagliptin in experimental models. Eur J Pharmacol. 2016;774:64–70.CrossrefWeb of SciencePubMedGoogle Scholar

  • [23]

    O’Neil PM, Aroda VR, Astrup A, Kushner R, Lau DC, Wadden TA, et al. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017;19:1529–36.CrossrefWeb of SciencePubMedGoogle Scholar

  • [24]

    Mansur RB, Ahmed J, Cha DS, Woldeyohannes HO, Subramaniapillai M, Lovshin J, et al. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study. J Affect Disord. 2017;207:114–20.PubMedWeb of ScienceCrossrefGoogle Scholar

  • [25]

    Mansur RB, Zugman A, Ahmed J, Cha DS, Subramaniapillai M, Lee Y, et al. Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders. Eur Neuropsychopharmacol. 2017;27:1153–62.Web of SciencePubMedCrossrefGoogle Scholar

  • [26]

    Rashid NA, Lim J, Lam M, Chong S-A, Keefe RS, Lee J. Unraveling the relationship between obesity, schizophrenia and cognition. Schizophr Res. 2013;151:107–12.CrossrefPubMedWeb of ScienceGoogle Scholar

  • [27]

    Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3:200–18.CrossrefPubMedGoogle Scholar

  • [28]

    Dixit TS, Sharma AN, Lucot JB, Elased KM. Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis. Physiol Behav. 2013;114:38–41.Web of SciencePubMedGoogle Scholar

  • [29]

    Babic I, Gorak A, Engel M, Sellers D, Else P, Osborne AL, et al. Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats. J Psychopharmacol. 2018;32:578–90.Web of ScienceCrossrefPubMedGoogle Scholar

  • [30]

    Sharma AN, Ligade SS, Sharma JN, Shukla P, Elased KM, Lucot JB. GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats. Metab Brain Dis. 2015;30:519–27.CrossrefWeb of SciencePubMedGoogle Scholar

  • [31]

    Ishøy PL, Knop FK, Vilsbøll T, Glenthøj BY, Ebdrup BH. Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes. Am J Psychiatry. 2013;170:681–2.Web of ScienceCrossrefGoogle Scholar

  • [32]

    Larsen JR, Vedtofte L, Jakobsen MS, Jespersen HR, Jakobsen MI, Svensson CK, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine-or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2017;74:719–28.Web of ScienceCrossrefGoogle Scholar

  • [33]

    Ishøy PL, Knop FK, Broberg BV, Bak N, Andersen UB, Jørgensen NR, et al. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2017;19:162–71.Web of SciencePubMedCrossrefGoogle Scholar

  • [34]

    Ishøy PL, Fagerlund B, Broberg BV, Bak N, Knop FK, Glenthøj BY, et al. No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. Acta Psychiatr Scand. 2017;136:52–62.PubMedWeb of ScienceCrossrefGoogle Scholar

  • [35]

    Messier C. Diabetes, Alzheimer’s disease and apolipoprotein genotype. Exp Gerontol. 2003;38:941–6.PubMedCrossrefGoogle Scholar

  • [36]

    Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer’s disease risk with obesity, diabetes, and related disorders. Biol Psychiatry. 2010;67:505–12.Web of SciencePubMedCrossrefGoogle Scholar

  • [37]

    Naderali EK, Ratcliffe SH, Dale MC. Obesity and Alzheimer’s disease: a link between body weight and cognitive function in old age. Am J Alzheimer’s Dis Other Dement. 2009;24:445–9.CrossrefGoogle Scholar

  • [38]

    McClean PL, Hölscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease. Neuropharmacology. 2014;76:57–67.Web of ScienceCrossrefPubMedGoogle Scholar

  • [39]

    Chen S, Sun J, Zhao G, Guo A, Chen Y, Fu R, Deng Y. Liraglutide improves water maze learning and memory performance while reduces hyperphosphorylation of tau and neurofilaments in APP/PS1/Tau triple transgenic mice. Neurochem Res. 2017;42:2326–35.CrossrefWeb of SciencePubMedGoogle Scholar

  • [40]

    McClean PL, Jalewa J, Hölscher C. Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice. Behav Brain Res. 2015;293:96–106.Web of SciencePubMedCrossrefGoogle Scholar

  • [41]

    Egefjord L, Gejl M, Møller A, Brændgaard H, Gottrup H, Antropova O, et al. Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer’s disease — protocol for a controlled, randomized double-blinded trial. Brain. 2012;12:14.Google Scholar

  • [42]

    Gejl M, Gjedde A, Egefjord L, Møller A, Hansen SB, Vang K, et al. In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci. 2016;8:108.PubMedWeb of ScienceGoogle Scholar

  • [43]

    Hsu TM, Noble EE, Liu CM, Cortella AM, Konanur VR, Suarez AN, et al. A hippocampus to prefrontal cortex neural pathway inhibits food motivation through glucagon-like peptide-1 signaling. Mol Psychiatry. 2017. doi: 10.1038/mp.2017.91 [Epub ahead of print].Web of SciencePubMedGoogle Scholar

  • [44]

    Robert SA, Rohana AG, Shah SA, Chinna K, Wan Mohamud WN, Kamaruddin NA. Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide – a pilot study. Obes Res Clin Pract. 2015;9:301–4.PubMedCrossrefWeb of ScienceGoogle Scholar

  • [45]

    Naessen S, Carlstrom K, Holst JJ, Hellström PM, Hirschberg AL. Women with bulimia nervosa exhibit attenuated secretion of glucagon-like peptide 1, pancreatic polypeptide, and insulin in response to a meal. Am J Clin Nutr. 2011;94:967–72.PubMedCrossrefWeb of ScienceGoogle Scholar

  • [46]

    Dossat AM, Bodell LP, Williams DL, Eckel LA, Keel PK. Preliminary examination of glucagon-like peptide-1 levels in women with purging disorder and bulimia nervosa. Int J Eat Disord. 2015;48:199–205.PubMedWeb of ScienceCrossrefGoogle Scholar

  • [47]

    Brambilla F, Monteleone P, Maj M. Glucagon-like peptide-1 secretion in bulimia nervosa. Psychiatry Res. 2009;169:82–5.Web of SciencePubMedCrossrefGoogle Scholar

About the article

Received: 2018-05-01

Accepted: 2018-06-18

Published Online: 2018-07-18


Author Statement

Research funding: The Neuropsychiatry Program & Immuno-Psychiatry Lab are supported by grants from the Department of Psychiatry & Behavioral Sciences, UT Health Houston.

Conflict of interest: The authors declare no conflict of interest.

Informed consent: Informed consent is not applicable.

Ethical approval: The conducted research is not related to either human or animals use.


Citation Information: Hormone Molecular Biology and Clinical Investigation, Volume 36, Issue 2, 20180031, ISSN (Online) 1868-1891, DOI: https://doi.org/10.1515/hmbci-2018-0031.

Export Citation

©2018 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Mei Zhou, Shuyi Chen, Peng Peng, Zhongya Gu, Jing Yu, Gang Zhao, and Yanqiu Deng
Biochemical and Biophysical Research Communications, 2019, Volume 511, Number 1, Page 154

Comments (0)

Please log in or register to comment.
Log in